Honors and awards
Dan Theodorescu MD PhD is the Director of the Samuel Oschin Comprehensive Cancer Institute and Cedars-Sinai Cancer enterprise in Los Angeles. From 2010 until 2018, he was Director of the University of Colorado Cancer Center and a Distinguished University Professor. Dr. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as discovery of new drugs for cancer. Examples include discovery of genes that regulate tumor growth and metastasis (RhoGDI2, AGL, GON4L) and novel biomarkers (DNA/NGS, RNA and proteomic) and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG 1314) clinical trials. He also conceptualized the approach and then led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in cancer. This drug was awarded a US patent and is in commercial development. Most recently he identified approaches that define effective combination therapy with checkpoint inhibitors. He is the founding co-editor in chief of Bladder Cancer, the first journal focused on this disease and an elected member of the Association of American Physicians (AAP), the American Association of Genitourinary Surgeons (AAGUS), the American Surgical Association (ASA) and the National Academy of Medicine (NAM).
Cedars-Sinai Medical Center (Primary)
Dermot Patrick Bracher McGovern, MBBS, DPhil (Oxon), FRCP (Lon) is the representative at this institution.